Skip to navigation Skip to content

Multiple myeloma (MM) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051124

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised daratumumab, elotuzumab, lenalidomide, pomalidomide and selinexor for patients with multiple myeloma (MM).

For details on how to process a PBS Authority, see:

On this page:

Multiple myeloma (MM) quick reference - Initial and Balance of Supply

Multiple myeloma (MM) quick reference - Continuing and no treatment phase

Newly diagnosed triple therapy (21-day cycle for 8 cycles)

Newly diagnosed triple therapy (28-day cycle for 6 cycles)

Multiple myeloma (MM) quick reference - Initial and Balance of Supply

Table 1

Restrictions

Treatment type

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self- serve

Initial

Newly

diagnosed

PB291 form

Monotherapy

Written

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Initial

Newly

diagnosed

PB200 form

Dual therapy with dexamethasone

Written

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Initial

Newly diagnosed

PB293 form

Triple therapy (this drug, bortezomib and dexamethasone)

Written

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Initial

Newly diagnosed

(week 0-24)

Triple therapy (this drug, lenalidomide and dexamethasone)

Telephone

Electronic

S85:

daratumumab

S100:

daratumumab

No

OPA

Not specified

Yes

Grandfather

Newly diagnosed

Triple therapy (this drug, lenalidomide and dexamethasone)

Telephone

Electronic

S85:

daratumumab

S100:

daratumumab

No

OPA

Not specified

Yes

Balance of Supply

Newly diagnosed

(cycles 5-6 or cycles 5-8)

Triple therapy (this drug, bortezomib and dexamethasone)

Telephone

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Initial

PB214

Dual therapy (this drug and dexamethasone)

Written

Electronic

S100:

pomalidomide

No

OPA

Not specified

Yes

Initial

Progressive disease

PB158 form

Monotherapy or dual combination therapy with dexamethasone

Written

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Initial

Progressive

disease

Triple therapy (this drug, bortezomib and dexamethasone))

Telephone

Electronic

S100:

pomalidomide

No

OPA

Not specified

Yes

Initial

Relapsed and/or refractory multiple myeloma

Dual therapy (this drug and dexamethasone)

Telephone

Electronic

S100:

selinexor

(general listing)

No

OPA

Not specified

Yes

Initial

Relapsed and/or refractory multiple myeloma

(week 1-9)

Triple therapy (this drug, bortezomib and dexamethasone)

Telephone

Electronic

S85:

daratumumab

S100:

daratumumab

(general listing)

No

OPA

Not specified

Yes

Initial

Relapsed and/or refractory multiple myeloma

Triple therapy (this drug, bortezomib and dexamethasone)

Telephone

Electronic

S100:

selinexor

(general listing)

No

OPA

Not specified

Yes

Multiple myeloma (MM) quick reference - Continuing and no treatment phase

Table 2

Restrictions

Treatment type

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self- serve

Continuing

Newly

diagnosed

Monotherapy

Telephone

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Continuing

Newly

diagnosed

Dual therapy with dexamethasone

Telephone

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Continuing

Newly diagnosed

(week 25 onwards)

Triple therapy (this drug, lenalidomide and dexamethasone)

Telephone

Electronic

S85:

daratumumab

S100:

daratumumab

No

OPA

Not specified

Yes

Continuing

Dual therapy (this drug and dexamethasone)

Telephone

Electronic

S100:

pomalidomide

No

OPA

Not specified

Yes

Continuing

Triple therapy (this drug, bortezomib and dexamethasone)

Telephone

Electronic

S100:

pomalidomide

No

OPA

Not specified

Yes

Continuing

Progressive disease

Monotherapy or dual combination therapy with dexamethasone

Telephone

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Relapsed and/or refractory multiple myeloma

Triple therapy (this drug, elotuzumab and dexamethasone)

Telephone

Electronic

S100:

Lenalidomide

No

OPA

Not specified

Yes

Relapsed and/or refractory multiple myeloma

Triple therapy (this drug, carfilzomib and dexamethasone)

Telephone

Electronic

S100:

lenalidomide

No

OPA

Not specified

Yes

Continuing

Relapsed and/or refractory multiple myeloma

Triple therapy (this drug, lenalidomide and dexamethasone)

Telephone

Electronic

S100 - EFC

elotuzumab. For commercial reasons as of 1 December 2024, initial treatment with elotuzumab as triple therapy is no longer PBS-subsidised. Continuing treatment with elotuzumab as triple therapy remains on the PBS to make sure continuity of the treatment for existing patients.

No

OPA

Not specified

Yes

Continuing

Relapsed and/or refractory multiple myeloma

Dual therapy (this drug and dexamethasone)

Telephone

Electronic

S100:

selinexor

(general listing)

No

OPA

Not specified

Yes

Continuing

Relapsed and/or refractory multiple myeloma

Triple therapy (this drug, bortezomib and dexamethasone)

Telephone

Electronic

S100:

selinexor

(general listing)

No

OPA

Not specified

Yes

Continuing

Relapsed and/or refractory multiple myeloma

(week 10-24)

Triple therapy (this drug, bortezomib and dexamethasone)

Telephone

Electronic

S85:

daratumumab

S100:

daratumumab

(general listing)

No

OPA

Not specified

Yes

Continuing

Relapsed and/or refractory multiple myeloma

(week 25 onwards)

Triple therapy (this drug, bortezomib and dexamethasone)

Telephone

Electronic

S85:

daratumumab

S100:

daratumumab

(general listing)

No

OPA

Not specified

Yes

Newly diagnosed triple therapy (21-day cycle for 8 cycles)

Table 3

Step

Treatment phase

Drug combination

Treatment cycle

Quantity and repeats

Authority level

1

Initial

lenalidomide, dexamethasone and bortezomib

Cycle 1 - 4
  • Quantity 14
  • Repeats 3

Written (PB293)

Electronic

2

Continuing triple

lenalidomide, dexamethasone and bortezomib

Cycle 5 - 8 (21-day)

OR

Cycle 5 - 6 (28-day)
  • Quantity 14
  • Repeats 3

OR

  • Quantity 21
  • Repeat 1

Telephone

Electronic

3

Continuing dual therapy (if continued on 21-day cycle)

OR

if changed to 28-day cycle

If ineligible for Stem Cell Transplant (SCT)

Initial newly diagnosed dual therapy

If post SCT

Initial newly diagnosed monotherapy

Continuing dual therapy

lenalidomide and dexamethasone

Ineligible for SCT

lenalidomide and dexamethasone

Post SCT

lenalidomide

Continuing dual therapy (21-day cycle)

Cycle 9 and beyond

Switching to 28-day cycle

N/A

Continuing dual therapy (21-day cycle)

  • Quantity 21
  • Repeats up to 5

Ineligible for SCT

  • Quantity 21
  • Repeats up to 5

Post SCT

  • Quantity 28
  • Repeats 2

Continuing dual therapy (21-day cycle)

Telephone

Electronic

Ineligible for SCT

Written (PB200)

Electronic

Post SCT

Written (PB291)

Electronic

Newly diagnosed triple therapy (28-day cycle for 6 cycles)

Table 4

Step

Treatment phase

Drug combination

Treatment cycle

Quantity and repeats

Authority level

1

Initial

lenalidomide, dexamethasone and bortezomib

Cycle 1 - 4
  • Quantity 21
  • Repeats 3

Written (PB293)

Electronic

2

Continuing triple

lenalidomide, dexamethasone and bortezomib

Cycle 5 - 6 (28-day)

OR

Cycle 5 - 8 (21-day)
  • Quantity 21
  • Repeat 1

OR

  • Quantity 14
  • Repeats 3

Telephone

Electronic

3

If continued on 28-day cycle

If ineligible for SCT

Initial newly diagnosed dual therapy

If post SCT

Initial newly diagnosed monotherapy

OR

Continuing dual therapy (if changed to 21-day cycle)

Ineligible for SCT

lenalidomide and dexamethasone

Post SCT

lenalidomide

Continuing dual therapy

lenalidomide and dexamethasone

Continuing 28-day cycle

N/A

Continuing dual therapy (21-day cycle)

Cycle 9 and beyond

Ineligible for SCT

  • Quantity 21
  • Repeats 5

Post SCT

  • Quantity 28
  • Repeats 2

Continuing dual therapy

  • Quantity 21
  • Repeats up to 5

Ineligible for SCT

Written (PB200)

Electronic

Post SCT

Written (PB291)

Electronic

Continuing dual therapy (21-day cycle)

Telephone

Electronic